No Data
Morgan Stanley Identifies 39 Stocks Likely to Face Tax Loss Selling Pressure
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
Repligen Analyst Ratings
RBC Capital Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $205
Repligen (NASDAQ:RGEN) Shareholder Returns Have Been Favorable, Earning 93% in 5 Years
Repligen Opens Training & Innovation Center to Elevate Customer Experience